Colestipol · Colestid, Colestipol Hydrochloride

What is Colestipol?

Colestipol is a positively charged anion-exchange resin that binds bile acids in the intestine to form an insoluble complex excreted in feces. It reduces elevated serum total and LDL cholesterol in patients with primary hypercholesterolemia who do not respond adequately to diet. It is also studied in early-stage HER2-positive breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Colestid, Colestipol Hydrochloride, NSC-147003

Drug type

Small molecule

Pathways

bile acid sequestration

Therapy area

Oncology

Developer

Pfizer

In trials of

PBYI

FDA status

Approved as Colestid, Colestipol Hydrochloride (April 4, 1977), NDA017563 · FDA label

UNII

K50N755924

✅ FDA-approved uses

• Primary hypercholesterolemia (Colestipol Hydrochloride)
• Primary hypercholesterolemia (Colestid)

From the indications section of the FDA label (version of May 13, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Early Stage HER2+ Breast Cancer

Sources

• FDA label Colestipol Hydrochloride (2025-05-13), indications
• FDA label Colestid (2024-10-24), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT02400476

Updated Oct 3, 2026.